August 22nd
TargeGen, Inc., Appoints Forrest H. Fuller, Ph.D. As Director of Business Development

August 7th
TargeGen, Inc., Appoints Mark R. Green, M.D. To Scientific Advisory Board

March 25th
TargeGen, Inc. Appoints Richard M. Soll, Ph.D. As Vice President of Research & Development and Chief Scientific Officer

February 24th
TargeGen, Inc. Appoints Anthony DeMaria, M.D. To Scientific Advisory Board

January 16th
TargeGen, Inc., Appoints David E. McClure, Ph.D. As Vice President of Regulatory Affairs & Drug Development

2002
November 19th
TargeGen, Inc. Appoints David F. Ranney, M.D. To Scientific Advisory Board

June 20th
TargeGen Inc., appoints Daniel D. Von Hoff, M.D. to scientific advisory board; renowned cancer expert to contribute to company's oncology program

June 6th
TargeGen announces management and scientific team additions, new facilities

April 3rd
TargeGen Inc. secures $10 million in Series A financing -- Company to develop therapeutics for cancer, cardiovascular and other diseases